Skip to main content
. 2022 Jan 10;37(1):379–385. doi: 10.1080/14756366.2021.2016734

Figure 4.

Figure 4.

The anti-tumour activity of β-elemene and compound Id against brain malignant glioma (n = 5). (A) Body weight (model group as 100%). (B) Brain weight. (C) Boluminescence signal intensity of brain tumour. (D) Inhibitory rates of β-elemene and compound Id from week 1 to week 3. (E) Representative brain glioma images of the model, β-elemene, and compound Id groups. (F) Histological analysis of the brain glioma tumour tissue (**P < 0.01 vs. model group; ##P < 0.01 vs. β-elemene group).